Strengths andWeaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy

被引:36
作者
Barutello, Giuseppina [1 ]
Rolih, Valeria [1 ]
Arigoni, Maddalena [1 ]
Tarone, Lidia [1 ]
Conti, Laura [1 ]
Quaglino, Elena [1 ]
Buracco, Paolo [2 ]
Cavallo, Federica [1 ]
Riccardo, Federica [1 ]
机构
[1] Univ Turin, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy
[2] Univ Turin, Dept Vet Sci, I-10095 Grugliasco, Italy
关键词
melanoma; pre-clinical models; immunotherapy; canine melanoma; comparative oncology; CSPG4; ORAL MALIGNANT-MELANOMA; CELL-DERIVED EXOSOMES; METASTATIC MELANOMA; COMPARATIVE ONCOLOGY; ANTITUMOR-ACTIVITY; DNA VACCINATION; VEMURAFENIB RESISTANCE; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; SELECTIVE INHIBITOR;
D O I
10.3390/ijms19030799
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several mouse models holding the promise to provide insight into molecular biology and clinical behavior of melanoma have been generated. The most relevant ones and their contribution for the advancement of therapeutic approaches for the treatment of human melanoma patients will be here summarized. However, as models, mice do not recapitulate all the features of human melanoma, thus their strengths and weaknesses need to be carefully identified and considered for the translation of the results into the human clinics. In this panorama, the concept of comparative oncology acquires a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational model for the pre-clinical investigation of melanoma progression and treatment will be here discussed, with a special consideration to the development of innovative immunotherapeutic approaches.
引用
收藏
页数:21
相关论文
共 155 条
[1]   Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background [J].
Ackermann, J ;
Frutschi, M ;
Kaloulis, K ;
McKee, T ;
Trumpp, A ;
Beermann, F .
CANCER RESEARCH, 2005, 65 (10) :4005-4011
[2]   Genomic Classification of Cutaneous Melanoma [J].
Akbani, Rehan ;
Akdemir, Kadir C. ;
Aksoy, B. Arman ;
Albert, Monique ;
Ally, Adrian ;
Amin, Samirkumar B. ;
Arachchi, Harindra ;
Arora, Arshi ;
Auman, J. Todd ;
Ayala, Brenda ;
Baboud, Julien ;
Balasundaram, Miruna ;
Balu, Saianand ;
Barnabas, Nandita ;
Bartlett, John ;
Bartlett, Pam ;
Bastian, Boris C. ;
Baylin, Stephen B. ;
Behera, Madhusmita ;
Belyaev, Dmitry ;
Benz, Christopher ;
Bernard, Brady ;
Beroukhim, Rameen ;
Bir, Natalie ;
Black, Aaron D. ;
Bodenheimer, Tom ;
Boice, Lori ;
Boland, Genevieve M. ;
Bono, Riccardo ;
Bootwalla, Moiz S. ;
Bosenberg, Marcus ;
Bowen, Jay ;
Bowlby, Reanne ;
Bristow, Christopher A. ;
Brockway-Lunardi, Laura ;
Brooks, Denise ;
Brzezinski, Jakub ;
Bshara, Wiam ;
Buda, Elizabeth ;
Burns, William R. ;
Butterfield, Yaron S. N. ;
Button, Michael ;
Calderone, Tiffany ;
Cappellini, Giancarlo Antonini ;
Carter, Candace ;
Carter, Scott L. ;
Cherney, Lynn ;
Cherniack, Andrew D. ;
Chevalier, Aaron ;
Chin, Lynda .
CELL, 2015, 161 (07) :1681-1696
[3]   Exosomes as potent cell-free peptide-based vaccine.: I.: Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells [J].
André, F ;
Chaput, N ;
Schartz, NEC ;
Flament, C ;
Aubert, N ;
Bernard, J ;
Lemonnier, F ;
Raposo, G ;
Escudier, B ;
Hsu, DH ;
Tursz, T ;
Amigorena, S ;
Angevin, E ;
Zitvogel, L .
JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2126-2136
[4]   MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].
Ascierto, Paolo A. ;
Schadendorf, Dirk ;
Berking, Carola ;
Agarwala, Sanjiv S. ;
van Herpen, Carla M. L. ;
Queirolo, Paola ;
Blank, Christian U. ;
Hauschild, Axel ;
Beck, J. Thaddeus ;
St-Pierre, Annie ;
Niazi, Faiz ;
Wandel, Simon ;
Peters, Malte ;
Zubel, Angela ;
Dummer, Reinhard .
LANCET ONCOLOGY, 2013, 14 (03) :249-256
[5]   Cancer immunology and canine malignant melanoma: A comparative review [J].
Atherton, Matthew J. ;
Morris, Joanna S. ;
McDermott, Mark R. ;
Lichty, Brian D. .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2016, 169 :15-26
[6]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[7]   Modeling Melanoma In Vitro and In Vivo [J].
Beaumont, Kimberley A. ;
Mohana-Kumaran, Nethia ;
Haass, Nikolas K. .
HEALTHCARE, 2014, 2 (01) :27-46
[8]   Patient-derived xenografts undergo mouse-specific tumor evolution [J].
Ben-David, Uri ;
Ha, Gavin ;
Tseng, Yuen-Yi ;
Greenwald, Noah F. ;
Oh, Coyin ;
Shih, Juliann ;
McFarland, James M. ;
Wong, Bang ;
Boehm, Jesse S. ;
Beroukhim, Rameen ;
Golub, Todd R. .
NATURE GENETICS, 2017, 49 (11) :1567-+
[9]   Comparative functional characterization of canine IgG subclasses [J].
Bergeron, Lisa M. ;
McCandless, Erin E. ;
Dunham, Steve ;
Dunkle, Bill ;
Zhu, Yaqi ;
Shelly, John ;
Lightle, Sandra ;
Gonzales, Andrea ;
Bainbridge, Graeme .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2014, 157 (1-2) :31-41
[10]   Canine oral melanoma [J].
Bergman, Philip J. .
CLINICAL TECHNIQUES IN SMALL ANIMAL PRACTICE, 2007, 22 (02) :55-60